REPLIGEN CORP acquires Novozymes Biopharma (Novozymes Biopharma Sweden AB)

REPLIGEN CORP acquired Novozymes Biopharma (Novozymes Biopharma Sweden AB) for ~$22.7 million (EUR 17 million) cash + up to EUR 4 million (~$5.6M) milestones, a transaction completed in December 2011, structured as all cash plus contingent milestones.

Novozymes Biopharma (Novozymes Biopharma Sweden AB) operates in Proteins / bioprocessing consumables, is based in Lund, Sweden. Acquisition of the bioprocessing business of Novozymes Biopharma Sweden AB, a supplier of cell-culture growth factors and other products used in the manufacture of biologic drugs. Repligen called it a transformative deal that elevated the company to a world-leading supplier of products for manufacturing biologic drugs and accelerated its path to sustainable profitability.

Repligen described the deal as positioning it 'as a leading producer of high value, consumable products that will directly benefit from the long-term growth of the biologics market,' delivering on its strategic objective to transition into a commercially focused company.

Established consumable-product revenue with exposure to long-term biologics manufacturing growth. Repligen bioprocessing operations (Sweden)

This acquisition positions Repligen as a leading producer of high value, consumable products that will directly benefit from the long-term growth of the biologics market. Earlier this year we announced our strategic objective to transition into a commercially focused company, and the acquisition of the Novozymes business will deliver on that goal.Walter C. Herlihy, President and CEO, Repligen Corporation

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.